AltheaDx, a San Diego-based developer of molecular diagnostics, reported yesterday that it had closed its $6 million Series A round of funding. Telegraph Hill Partners, of San Francisco, led the funding round. In September, AltheaDx filed papers with the SEC to report $3.6 million it had raised in the first-round financing. Magda Marquet, founder and co-CEO of AltheaDx, said in a statement yesterday that the fresh capital will support the firm’s partnerships with pharmaceutical companies to develop diagnostics that help predict whether a drug is safe for certain people.
Author: Ryan McBride
Ryan is an award-winning business journalist who contributes to our life sciences and technology coverage. He was previously a staff writer for Mass High Tech, a Boston business and technology newspaper, where he and his colleagues won a national business journalism award from the Society of American Business Editors and Writers in 2008. In recent years, he has made regular TV appearances on New England Cable News.
Prior to MHT, Ryan covered the life sciences, technology, and energy sectors for Providence Business News. He graduated with honors from the University of Rhode Island in 2001 with a bachelor’s degree in communications. When he’s not chasing down news, Ryan enjoys mountain biking and skiing in his home state of Vermont.
View all posts by Ryan McBride
